{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T12:23:12Z","timestamp":1792153392512,"version":"4.4.0"},"reference-count":56,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1097\/mot.0b013e3283626149","type":"journal-article","created":{"date-parts":[[2013,5,21]],"date-time":"2013-05-21T17:42:07Z","timestamp":1369158127000},"page":"470-477","source":"Crossref","is-referenced-by-count":62,"title":["Posttransplant monitoring of de novo human leukocyte antigen donor-specific antibodies in kidney transplantation"],"prefix":"10.1097","volume":"18","author":[{"given":"Chris","family":"Wiebe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Nickerson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-14-20211004","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1056\/NEJM196904032801401","article-title":"Significance of the positive crossmatch test in kidney transplantation.","volume":"280","author":"Patel","year":"1969","journal-title":"N Engl J Med"},{"key":"R2-14-20211004","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1097\/00007890-198707000-00012","article-title":"Posttransplant antidonor lymphocytotoxic antibody production in relation to graft outcome.","volume":"44","author":"Martin","year":"1987","journal-title":"Transplantation"},{"key":"R3-14-20211004","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1056\/NEJM199002223220805","article-title":"T-lymphocyte-antigen interactions in transplant rejection.","volume":"322","author":"Krensky","year":"1990","journal-title":"N Engl J Med"},{"key":"R4-14-20211004","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1146\/annurev.iy.04.040186.001003","article-title":"Effector mechanisms in allograft rejection.","volume":"4","author":"Mason","year":"1986","journal-title":"Annu Rev Immunol"},{"key":"R5-14-20211004","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/j.1365-2249.1991.tb02954.x","article-title":"Vascular deposition of complement-split products in kidney allografts with cell-mediated rejection.","volume":"86","author":"Feucht","year":"1991","journal-title":"Clin Exp Immunol"},{"key":"R6-14-20211004","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1111\/j.1600-6143.2006.01688.x","article-title":"Banff 05 meeting report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy (CAN).","volume":"7","author":"Solez","year":"2007","journal-title":"Am J Transplant"},{"key":"R7-14-20211004","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.coi.2010.08.009","article-title":"Non-MHC antigenic targets of the humoral immune response in transplantation.","volume":"22","author":"Zhang","year":"2010","journal-title":"Curr Opin Immunol"},{"key":"R8-14-20211004","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/ajt.12160","article-title":"Antibodies beyond HLA.","volume":"13","author":"Nickerson","year":"2013","journal-title":"Am J Transplant"},{"key":"R9-14-20211004","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1111\/j.1600-6143.2012.04013.x","article-title":"Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant.","volume":"12","author":"Wiebe","year":"2012","journal-title":"Am J Transplant"},{"key":"R10-14-20211004","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1097\/TP.0b013e31827d62e3","article-title":"Incidence and impact of de novo donor-specific alloantibody in primary renal allografts.","volume":"95","author":"Everly","year":"2013","journal-title":"Transplantation"},{"key":"R11-14-20211004","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/j.1600-6143.2012.04325.x","article-title":"Microcirculation inflammation associates with outcome in renal transplant patients with de novo donor-specific antibodies.","volume":"13","author":"de Kort","year":"2013","journal-title":"Am J Transplant"},{"key":"R12-14-20211004","doi-asserted-by":"crossref","first-page":"3355","DOI":"10.1111\/j.1600-6143.2012.04251.x","article-title":"Posttransplant de novo donor-specific HLA antibodies identify pediatric kidney recipients at risk for late antibody-mediated rejection.","volume":"12","author":"Ginevri","year":"2012","journal-title":"Am J Transplant"},{"key":"R13-14-20211004","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1038\/ki.2012.190","article-title":"Donor-specific HLA-DQ antibodies may contribute to poor graft outcome after renal transplantation.","volume":"82","author":"DeVos","year":"2012","journal-title":"Kidney Int"},{"key":"R14-14-20211004","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1097\/TP.0b013e3182543950","article-title":"De novo DQ donor-specific antibodies are associated with a significant risk of antibody-mediated rejection and transplant glomerulopathy.","volume":"94","author":"Willicombe","year":"2012","journal-title":"Transplantation"},{"key":"R15-14-20211004","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1097\/TP.0b013e3182139da1","article-title":"Inferior kidney allograft outcomes in patients with de novo donor-specific antibodies are due to acute rejection episodes.","volume":"91","author":"Cooper","year":"2011","journal-title":"Transplantation"},{"key":"R16-14-20211004","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1097\/TP.0b013e3182126ed0","article-title":"Natural history of proteinuria in renal transplant recipients developing de novo human leukocyte antigen antibodies.","volume":"91","author":"Fotheringham","year":"2011","journal-title":"Transplantation"},{"key":"R17-14-20211004","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1097\/TP.0b013e3181c3503e","article-title":"Screening for de novo antihuman leukocyte antigen antibodies in nonsensitized kidney transplant recipients does not predict acute rejection.","volume":"89","author":"Gill","year":"2010","journal-title":"Transplantation"},{"key":"R18-14-20211004","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1097\/01.TP.0000055833.65192.3B","article-title":"Posttransplantation production of donor hla-specific antibodies as a predictor of renal transplant outcome.","volume":"75","author":"Worthington","year":"2003","journal-title":"Transplantation"},{"key":"R19-14-20211004","first-page":"336","article-title":"Posttransplant donor-specific antibody production and graft outcome in kidney transplantation: results of sixteen-year monitoring by flow cytometry.","volume":"323-","author":"Piazza","year":"2006","journal-title":"Clin Transpl"},{"key":"R20-14-20211004","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1097\/TP.0b013e31827be3c1","article-title":"Rituximab prevents an anamnestic response in patients with cryptic sensitization to HLA.","volume":"95","author":"Zachary","year":"2013","journal-title":"Transplantation"},{"key":"R21-14-20211004","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1111\/j.1600-6143.2012.04181.x","article-title":"Patterns of de novo allo B cells and antibody formation in chronic cardiac allograft rejection after alemtuzumab treatment.","volume":"12","author":"Kwun","year":"2012","journal-title":"Am J Transplant"},{"key":"R22-14-20211004","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1111\/j.1600-6143.2011.03961.x","article-title":"Donor-specific HLA antibodies in a cohort comparing everolimus with cyclosporine after kidney transplantation.","volume":"12","author":"Liefeldt","year":"2012","journal-title":"Am J Transplant"},{"key":"R23-14-20211004","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/j.1600-6143.2011.03840.x","article-title":"Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence.","volume":"12","author":"Sellares","year":"2012","journal-title":"Am J Transplant"},{"key":"R24-14-20211004","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1111\/j.1600-6143.2009.02800.x","article-title":"De novo donor-specific antibody at the time of kidney transplant biopsy associates with microvascular pathology and late graft failure.","volume":"9","author":"Hidalgo","year":"2009","journal-title":"Am J Transplant"},{"key":"R25-14-20211004","first-page":"199","article-title":"Donor-specific HLA antibodies in chronic renal allograft rejection: A prospective trial with a four-year follow-up.","volume":"171-","author":"Lachmann","year":"2006","journal-title":"Clin Transpl"},{"key":"R26-14-20211004","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1097\/TP.0b013e3181a44206","article-title":"Antihuman leukocyte antigen and donor-specific antibodies detected by luminex posttransplant serve as biomarkers for chronic rejection of renal allografts.","volume":"87","author":"Lachmann","year":"2009","journal-title":"Transplantation"},{"key":"R27-14-20211004","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1111\/j.1600-6143.2007.01855.x","article-title":"Value of posttransplant antibody tests in the evaluation of patients with renal graft dysfunction.","volume":"7","author":"Scornik","year":"2007","journal-title":"Am J Transplant"},{"key":"R28-14-20211004","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1097\/TP.0b013e318203fd26","article-title":"C1q-fixing human leukocyte antigen antibodies are specific for predicting transplant glomerulopathy and late graft failure after kidney transplantation.","volume":"91","author":"Yabu","year":"2011","journal-title":"Transplantation"},{"key":"R29-14-20211004","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1046\/j.1523-1755.2001.059002488.x","article-title":"Unusual expression of human lymphocyte antigen class II in normal renal microvascular endothelium.","volume":"59","author":"Muczynski","year":"2001","journal-title":"Kidney Int"},{"key":"R30-14-20211004","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1111\/j.1600-6143.2005.01016.x","article-title":"Serial ten-year follow-up of HLA and MICA antibody production prior to kidney graft failure.","volume":"5","author":"Mizutani","year":"2005","journal-title":"Am J Transplant"},{"key":"R31-14-20211004","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1097\/TP.0b013e3181b11b72","article-title":"HLA-specific antibodies developed in the first year posttransplant are predictive of chronic rejection and renal graft loss.","volume":"88","author":"Lee","year":"2009","journal-title":"Transplantation"},{"key":"R32-14-20211004","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1111\/j.1600-6143.2009.02799.x","article-title":"Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure.","volume":"9","author":"Einecke","year":"2009","journal-title":"Am J Transplant"},{"key":"R33-14-20211004","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1111\/j.1432-2277.2008.00755.x","article-title":"Poor graft outcome in recipients with de novo donor-specific anti-HLA antibodies after living related kidney transplantation.","volume":"21","author":"Li","year":"2008","journal-title":"Transpl Int"},{"key":"R34-14-20211004","first-page":"2561","article-title":"Does everolimus increase donor-specific HLA antibodies in kidney transplant recipients Am J T","volume":"12","author":"Pascual","year":"2012","journal-title":"ransplant"},{"key":"R35-14-20211004","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1111\/j.1600-6143.2011.03637.x","article-title":"Efficacy and safety of early cyclosporine conversion to sirolimus with continued mmf-four-year results of the postconcept study.","volume":"11","author":"Lebranchu","year":"2011","journal-title":"Am J Transplant"},{"key":"R36-14-20211004","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1111\/j.1600-6143.2009.02764.x","article-title":"Proinflammatory events are associated with significant increases in breadth and strength of hla-specific antibody.","volume":"9","author":"Locke","year":"2009","journal-title":"Am J Transplant"},{"key":"R37-14-20211004","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1111\/j.1600-6143.2011.03604.x","article-title":"De novo anti-HLA antibody after pandemic H1N1 and seasonal influenza immunization in kidney transplant recipients.","volume":"11","author":"Katerinis","year":"2011","journal-title":"Am J Transplant"},{"key":"R38-14-20211004","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1681\/ASN.2004121130","article-title":"Frequency and clinical implications of development of donor-specific and nondonor-specific HLA antibodies after kidney transplantation.","volume":"16","author":"Hourmant","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"R39-14-20211004","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/TP.0b013e31823bb647","article-title":"Early subclinical rejection as a risk factor for late chronic humoral rejection.","volume":"93","author":"Moreso","year":"2012","journal-title":"Transplantation"},{"key":"R40-14-20211004","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1111\/j.1600-6143.2007.02137.x","article-title":"Peritubular capillaritis in renal allografts: Prevalence, scoring system, reproducibility and clinicopathological correlates.","volume":"8","author":"Gibson","year":"2008","journal-title":"Am J Transplant"},{"key":"R41-14-20211004","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1097\/01.ASN.0000061778.08085.9F","article-title":"Normal human kidney hla-dr-expressing renal microvascular endothelial cells: characterization, isolation, and regulation of MHC class II expression.","volume":"14","author":"Muczynski","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"R42-14-20211004","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1111\/j.1600-6143.2009.02694.x","article-title":"Diagnosing rejection in renal transplants: a comparison of molecular- and histopathology-based approaches.","volume":"9","author":"Reeve","year":"2009","journal-title":"Am J Transplant"},{"key":"R43-14-20211004","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1111\/j.1600-6143.2008.02303.x","article-title":"Four stages and lack of stable accommodation in chronic alloantibody-mediated renal allograft rejection in cynomolgus monkeys.","volume":"8","author":"Smith","year":"2008","journal-title":"Am J Transplant"},{"key":"R44-14-20211004","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1111\/j.1432-2277.2005.00085.x","article-title":"Prevalence and significance of anti-HLA and donor-specific antibodies long-term after renal transplantation.","volume":"18","author":"Cardarelli","year":"2005","journal-title":"Transpl Int"},{"key":"R45-14-20211004","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1111\/j.1600-6143.2006.01503.x","article-title":"Posttransplant anti-HLA class II antibodies as risk factor for late kidney allograft failure.","volume":"6","author":"Campos","year":"2006","journal-title":"Am J Transplant"},{"key":"R46-14-20211004","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1097\/00007890-199103000-00011","article-title":"Soluble HLA antigens, anti-HLA antibodies, and antiidiotypic antibodies in the circulation of renal transplant recipients.","volume":"51","author":"Suciu-Foca","year":"1991","journal-title":"Transplantation"},{"key":"R47-14-20211004","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/j.1600-6143.2006.01644.x","article-title":"Four-year follow-up of a prospective trial of HLA and MICA antibodies on kidney graft survival.","volume":"7","author":"Terasaki","year":"2007","journal-title":"Am J Transplant"},{"key":"R48-14-20211004","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1399-3046.2011.01599.x","article-title":"Complement-fixing donor-specific antibodies identified by a novel c1q assay are associated with allograft loss.","volume":"16","author":"Sutherland","year":"2012","journal-title":"Pediatr Transplant"},{"key":"R49-14-20211004","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.healun.2010.08.020","article-title":"Clinical usefulness of a novel c1q assay to detect immunoglobulin G antibodies capable of fixing complement in sensitized pediatric heart transplant patients.","volume":"30","author":"Chin","year":"2011","journal-title":"J Heart Lung Transplant"},{"key":"R50-14-20211004","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1111\/j.1600-6143.2011.03985.x","article-title":"Pretransplant donor-specific HLA class-i and -II antibodies are associated with an increased risk for kidney graft failure.","volume":"12","author":"Otten","year":"2012","journal-title":"Am J Transplant"},{"key":"R51-14-20211004","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1097\/TP.0b013e3181dc13e7","article-title":"C4d-fixing capability of low-level donor-specific HLA antibodies is not predictive for early antibody-mediated rejection.","volume":"89","author":"Honger","year":"2010","journal-title":"Transplantation"},{"key":"R52-14-20211004","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1097\/00007890-200210270-00025","article-title":"All chronic rejection failures of kidney transplants were preceded by the development of HLA antibodies.","volume":"74","author":"Lee","year":"2002","journal-title":"Transplantation"},{"key":"R53-14-20211004","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/TP.0b013e3181c6ff8d","article-title":"Proteasome inhibitor-based primary therapy for antibody-mediated renal allograft rejection.","volume":"89","author":"Walsh","year":"2010","journal-title":"Transplantation"},{"key":"R54-14-20211004","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1111\/j.1600-6143.2009.02577.x","article-title":"Reducing de novo donor-specific antibody levels during acute rejection diminishes renal allograft loss.","volume":"9","author":"Everly","year":"2009","journal-title":"Am J Transplant"},{"key":"R55-14-20211004","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1111\/j.1600-6143.2011.03525.x","article-title":"Summary of FDA antibody-mediated rejection workshop.","volume":"11","author":"Archdeacon","year":"2011","journal-title":"Am J Transplant"},{"key":"R56-14-20211004","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/TP.0b013e31827a19cc","article-title":"Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation.","volume":"95","author":"Tait","year":"2013","journal-title":"Transplantation"}],"container-title":["Current Opinion in Organ Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00075200-201308000-00014","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,6]],"date-time":"2021-10-06T09:51:21Z","timestamp":1633513881000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00075200-201308000-00014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8]]},"references-count":56,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/mot.0b013e3283626149","relation":{},"ISSN":["1087-2418"],"issn-type":[{"value":"1087-2418","type":"print"}],"subject":[],"published":{"date-parts":[[2013,8]]}}}